Enhanced angiogenesis with dl-3n-butylphthalide treatment after focal cerebral ischemia in RHRSP

Liao, Songjie; Lin, Jianwen; Pei, Zhong; Liu, Chunling; Zeng, Jinsheng; Huang, Ruxun

doi:10.1016/j.brainres.2009.06.018

Cited by 72 publications

(54 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The positive effects of NBP on cerebral ischemia, including improvement of microcirculation and energy metabolism, reduction of oxidative damage and neuronal apoptosis and inhibition of the inflammatory response, have been verified in experimental models and pharmacodynamic studies (1)(2)(3)(4)(5). Our previous studies demonstrated that NBP significantly inhibits caspase-3-mediated apoptosis, and decreases stroke-induced neuron loss and autophagic activity following cerebral ischemia in diabetic rats (22,23); and attenuates amyloid-β-induced activation of Table V.…”

Section: Discussionmentioning

confidence: 96%

“…The racemic compound DL-3-n-butylphthalide (NBP), which has multiple effects on various pathophysiological processes, is considered to be beneficial for the treatment of ischemic stroke, since it has been shown to protect neuronal cells against ischemia-induced brain damage and neurotoxic damage, improve cerebral blood flow, decrease brain edema and preserve the blood brain barrier (1)(2)(3)(4)(5). Cerebrolysin is a peptide-containing preparation that also exerts beneficial effects on ischemic stroke; preclinical studies have shown that Cerebrolysin substantially improves neurological outcome and promotes neurological functional recovery following ischemia by preventing cell death, the formation of free radicals, inflammation and by counteracting excitotoxicity (6)(7)(8)(9).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy and safety comparison of DL-3-n-butylphthalide and Cerebrolysin: Effects on neurological and behavioral outcomes in acute ischemic stroke

Xue

Zhang

Zhao

et al. 2016

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. Cerebrolysin and DL-3-n-butylphthalide (NBP) have each shown neuroprotective efficacy in preclinical models of acute ischemic stroke (AIS) and passed clinical trials as therapeutic drugs for AIS. The present study was a clinical trial to assess and compare the efficacy and safety of NBP and Cerebrolysin in the reduction of neurological and behavioral disability following AIS. A randomized, double-blind trial was conducted with enrolment of 60 patients within 12 h of AIS. In addition to routine treatment, patients were randomly assigned to receive a 10-day intravenous administration of NBP, Cerebrolysin or placebo. National Institutes of Health Stroke Scale (NIHSS) and Barthel Index (BI) scores were used to evaluate the efficacy of the treatment in the patients with AIS at 11 and 21 days after the initiation of therapy. Adverse events were also analyzed among the three groups. After 10 days of treatment with NBP or Cerebrolysin, the NIHSS and BI scores at day 21 showed statistical differences compared with those in the placebo group (P<0.05). The improvements of NIHSS and BI scores in the NBP and Cerebrolysin groups were higher than those in the placebo group at days 11 and 21 (P<0.05). A statistically significant difference in the improvement of 21-day NIHSS scores was observed between the two treatment groups (P<0.05). No significant difference was found among the three groups with regard to the rate of adverse events. Favorable outcomes and good safety were observed in the patients with moderate AIS treated with NBP or Cerebrolysin. The results indicate that NBP may be more effective than Cerebrolysin in improving short-term outcomes following AIS. This trial is registered at ClinicalTrials.gov with clinical trial identifier number NCT02149875.

show abstract

Section: Discussionmentioning

confidence: 96%

Section: Introductionmentioning

confidence: 99%

Efficacy and safety comparison of DL-3-n-butylphthalide and Cerebrolysin: Effects on neurological and behavioral outcomes in acute ischemic stroke

Xue

Zhang

Zhao

et al. 2016

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

show abstract

“…In a middle cerebral artery occlusion (MCAO) model with Stroke-prone renovascular hypertensive rats, NBP treatment rescues brain tissue after ischemic stroke by enhancing angiogenesis with up-regulation of VEGF and hypoxia inducible factor 1 (HIF1) alpha [11]. Therefore, angiogenesis induced by proangiographic immune factors play an important role in the mechanism of NBP in treatment of ischemic cerebrovascular diseases.…”

Section: Butylphthalidepromote Angiogenesis With Increasing Exprementioning

confidence: 99%

A Brief Discussion of Mechanism of Butylphthalide in Treatment of Ischemic Cerebrovascular Disease and its Potential Clinical Applicationin Treatment of Multiple Sclerosis

Wang¹,

Zhang²,

Tan³

2016

JCCR

View full text Add to dashboard Cite

A Chinese traditional medicine Butylphthalide (NBP) has been proved effects in ischemic cerebrovascular disease. Here we discuss the mechanism of NBP in treatment of ischemic stroke, and find its capability in penetrating and modulating Blood-brain barrier (BBB), reducing harmful inflammation and formation of scars in injury CNS tissue, which implicate the potential application of NBP in treatment of Multiple Sclerosis (MS).

show abstract

“…NBP is a new drug which could increase the blood flow of the ischemic area to improve energy metabolism [3], promote microvascular regeneration to reconstruct ischemic microcirculation [4,5], and protect the mitochondria to rescue ischemic penumbra cells. In addition, NBP could reduce the infarct volume, local cerebral ischemia, brain edema and inflammation in animal models [6].…”

Section: Introduction Of 3-n-butylphthalidementioning

confidence: 99%

The Neuroprotective Effect and Probable Mechanism of <smlcap>DL</smlcap>-3-n-Butylphthalide in Brain Diseases

et al. 2014

View full text Add to dashboard Cite

show abstract

Enhanced angiogenesis with dl-3n-butylphthalide treatment after focal cerebral ischemia in RHRSP

Cited by 72 publications

References 27 publications

Efficacy and safety comparison of DL-3-n-butylphthalide and Cerebrolysin: Effects on neurological and behavioral outcomes in acute ischemic stroke

Efficacy and safety comparison of DL-3-n-butylphthalide and Cerebrolysin: Effects on neurological and behavioral outcomes in acute ischemic stroke

A Brief Discussion of Mechanism of Butylphthalide in Treatment of Ischemic Cerebrovascular Disease and its Potential Clinical Applicationin Treatment of Multiple Sclerosis

The Neuroprotective Effect and Probable Mechanism of <smlcap>DL</smlcap>-3-n-Butylphthalide in Brain Diseases

Contact Info

Product

Resources

About